Drug Patents owned by Exela Pharma

1. List of Elcys drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10583155 EXELA PHARMA Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(15 years from now)

US10905714 EXELA PHARMA Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(15 years from now)

US10653719 EXELA PHARMA Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(15 years from now)

US10918662 EXELA PHARMA Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(15 years from now)

US10933089 EXELA PHARMA Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(15 years from now)

US10905713 EXELA PHARMA Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(15 years from now)

US10912795 EXELA PHARMA Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(15 years from now)

US11510942 EXELA PHARMA NA
Jan, 2039

(15 years from now)

US10478453 EXELA PHARMA Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(15 years from now)

US11510941 EXELA PHARMA NA
Jan, 2039

(15 years from now)

Drugs and Companies using CYSTEINE HYDROCHLORIDE ingredient

Market Authorisation Date: 16 April, 2019

Treatment: Method of using l-cysteine in an admixture for treating patients needing parenteral nutrition

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of ELCYS before it's patent expiration?
More Information on Dosage

2. List of Ganzyk-rtu drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9486530 EXELA PHARMA Ganciclovir compositions and related methods
Sep, 2034

(11 years from now)

Drugs and Companies using GANCICLOVIR ingredient

Market Authorisation Date: 17 February, 2017

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in